Sunday, November 22, 2026
Via News Knowledge File

Novo Nordisk

organization80% conf.·synced Aug 13, 2026

Pharmaceutical company manufacturing Wegovy (semaglutide) for weight management and type 2 diabetes

28
sourced metrics
451
relationships
20
stated objectives
8
Via News reports
Working data, not the finished story. This is what our AI has read and extracted from source documents so far. Before anything here becomes news, it is checked against the original source, fact-checked and put in context. Figures can be incomplete or wrongly labelled at this stage; our articles are the end product. How we source

Key metrics · each point sourced

Market Share
94%
Analyst Price Target
$48.84
Stock Price
$36.04
Net Income
48.56Bmillion DKK
May 17, 2026source
Revenue
96.82Bmillion DKK
May 17, 2026source
Dcf Intrinsic Value
769,110DKK per share
Apr 29, 2026source
Discount To Intrinsic Value
65.4%
Apr 29, 2026source
Free Cash Flow
52.1Bbillion DKK
Apr 29, 2026source
Free Cash Flow Projected
107.4Bbillion DKK
Apr 29, 2026source
Free Cash Flow Extrapolated
145.9Bbillion DKK
Apr 29, 2026source
Stock Price 52 Week Low
$35.12
Apr 1, 2026source
Pharmacy Distribution Network
70Bpharmacies
Mar 19, 2026source
Us Facilities
10locations
Mar 19, 2026source
Countries Marketing
170countries
Feb 24, 2026source
Employee Count Us
10,000employees
Feb 24, 2026source
Employee Count
68,800employees
Feb 24, 2026source
Countries Operating
80countries
Feb 24, 2026source
Profit Growth
-5%
Feb 4, 2026source

Stated objectives

Complete primary endpoint for CLEOPATTRA Phase 3 trial of coramitug in ATTR-CM

source
by 2029-01-01 00:00:00stated

Expand access to Wegovy and Ozempic for patients whose out-of-pocket costs are linked to list price, particularly those with high-deductible health plans or co-insurance benefit designs

source
by 2027-01-01 00:00:00stated

Remove cost barriers to connect more people with innovative medicines through lower list prices

source
target: 675 USD per month by 2027-01-01 00:00:00stated

Continue to explore new therapies that deliver on weight loss needs while reducing the risk of obesity-related health issues like cardiovascular disease

source
stated

Investigate the effect of CagriSema on cardiovascular outcomes in patients with established cardiovascular disease through REDEFINE 3 trial

source
stated

Develop zaltenibart into a differentiated and potentially best-in-class treatment approach for rare blood and kidney disorders

source
stated

Deepen understanding of the many factors that shape the lived experience of obesity and strengthen support and care for the obesity community

source
stated

Drive more inclusive, compassionate approaches to obesity care that are tailored to individual circumstances

source
stated

Initiate late-stage clinical trials of experimental obesity drug amycretin in injectable and oral forms

source
by 2026-03-31 00:00:00stated

Expand manufacturing capacity to strengthen leadership in diabetes and obesity care market for GLP-1 products

source
stated

Relationship graph · 451 connections

Developed by
175
Competes with
107
Regulates
23
Headquartered in
22
Employs
16
Customer of
13
Covered by
13
Supplies to
12

Via News coverage

This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →